Literature DB >> 16253755

Effects of active MEK1 expression in vivo.

Florence A Scholl1, Phillip A Dumesic, Paul A Khavari.   

Abstract

Cell transformation is often a result of constitutive activation of genes in signaling pathways that regulate cell proliferation and differentiation. Indeed, the Ras/Raf/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway is constitutively activated in a large number of cancers. The extent to which a single-gene mutation can alter cell fate, however, remains questionable. In vitro studies have addressed this issue, but organs are comprised of multiple cell types, and in vitro models often poorly approximate these interactions. In response to these limitations, cell-type specific mouse models have been generated as a means to examine the effect of altering a single element of the MAPK pathway in vivo. This review summarizes data from transgenic murine and human tissue models expressing constitutive active forms of MEK1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16253755     DOI: 10.1016/j.canlet.2004.12.013

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

1.  MAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy.

Authors:  Xinling Zhang; Leina Ma; Jieqiong Qi; Hui Shan; Wengong Yu; Yuchao Gu
Journal:  Mol Cell Biochem       Date:  2015-08-29       Impact factor: 3.396

2.  The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.

Authors:  Savita Bhalla; Andrew M Evens; Bojie Dai; Sheila Prachand; Leo I Gordon; Ronald B Gartenhaus
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

3.  Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.

Authors:  Rachel N Grisham; Kathleen N Moore; Michael S Gordon; Wael Harb; Gwendolyn Cody; Darragh F Halpenny; Vicky Makker; Carol A Aghajanian
Journal:  Clin Cancer Res       Date:  2018-05-29       Impact factor: 12.531

4.  Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer.

Authors:  Jer-Yen Yang; Chun-Ju Chang; Weiya Xia; Yan Wang; Kwok-Kin Wong; Jeffrey A Engelman; Yi Du; Michael Andreeff; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

5.  ATM regulates a DNA damage response posttranscriptional RNA operon in lymphocytes.

Authors:  Krystyna Mazan-Mamczarz; Patrick R Hagner; Yongqing Zhang; Bojie Dai; Elin Lehrmann; Kevin G Becker; Jack D Keene; Myriam Gorospe; Zhenqui Liu; Ronald B Gartenhaus
Journal:  Blood       Date:  2011-01-05       Impact factor: 22.113

6.  Mitogen-activated protein/extracellular signal-regulated kinase kinase 1act/tubulin interaction is an important determinant of mitotic stability in cultured HT1080 human fibrosarcoma cells.

Authors:  Jia-Ning Cao; Norazizah Shafee; Larry Vickery; Stefan Kaluz; Ning Ru; Eric J Stanbridge
Journal:  Cancer Res       Date:  2010-06-22       Impact factor: 12.701

7.  Delayed and persistent ERK1/2 activation is required for 4-hydroxytamoxifen-induced cell death.

Authors:  Jian-Hua Zhou; David V Yu; Jingwei Cheng; David J Shapiro
Journal:  Steroids       Date:  2007-07-07       Impact factor: 2.668

Review 8.  Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy.

Authors:  Claudia Trojaniello; Jason J Luke; Paolo A Ascierto
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

9.  Low expression of ERK signaling pathway affecting proliferation, cell cycle arrest and apoptosis of human gastric HGC-27 cells line.

Authors:  BeiLi Zhang; Yan Gu
Journal:  Mol Biol Rep       Date:  2014-02-20       Impact factor: 2.316

10.  ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation.

Authors:  Jer-Yen Yang; Cong S Zong; Weiya Xia; Hirohito Yamaguchi; Qingqing Ding; Xiaoming Xie; Jing-Yu Lang; Chien-Chen Lai; Chun-Ju Chang; Wei-Chien Huang; Hsin Huang; Hsu-Ping Kuo; Dung-Fang Lee; Long-Yuan Li; Huang-Chun Lien; Xiaoyun Cheng; King-Jen Chang; Chwan-Deng Hsiao; Fuu-Jen Tsai; Chang-Hai Tsai; Aysegul A Sahin; William J Muller; Gordon B Mills; Dihua Yu; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Nat Cell Biol       Date:  2008-01-20       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.